Factor XIII in Major Burns Coagulation

Hospital Universitari Vall d'Hebron Research Institute20 enrolled

Overview

Prospective observational study in which FXIII levels and coagulation tests and cicatrization are measured during the 30 days after the thermal trauma.

This is a prospective observational pilot study in which the levels of FXIII and coagulation, anticoagulation, fibrinolysis, endothelial tissue damage and cicatrization are at the arrival of the patient to hospital, 24 hours before the first surgical intervention, 24h After the first surgical intervention, at 7 days after the first intervention and at 30 days after the thermal trauma, in this moment the healing will also be evaluated. All burn patients who meet the proposed inclusion criteria will be included and entered into the Burn Unit of the Vall d'Hebron University Hospital from the start of the study until reaching a minimum of 20 cases or a temporary term of 2 years.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Burns Coagulation Disorder Factor XIII Deficiency Cicatrization Endothelial Dysfunction

Interventions

Coagulation testsDIAGNOSTIC_TEST

The following plasma values will be measured: prothrombin time, activated partial thromboplastin time, thrombin time, functional fibrinogen, lactate, base excess, fibrin monomers, Factor XIII, Factor XII, Factor VIII, Fact von Willebrand, Plasmin, Plasminogen, Alpha-2-antiplasmin, antithrombin, protein C, Heparan sulfate, synecan 1. Surveys on the state of healing and moisture titration will be performed using Tewamether

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Burned patients with a burned body surface of 20% or more * Over 18 years of age Exclusion Criteria: * ABSI (Abbreviated Burns Severity Index) greater than or equal to 12 * Associated polytrauma * Coagulation deficit previously known * Treatment with anticoagulants * Electrocution burns * Admission into the unit after hour 6 after thermal trauma * The refusal of the patient, familiar or responsible to participate in the study

Outcomes

Primary Outcomes

Factor XIII

Blood Coagulation Factor XIII levels

Time frame: 30 days

Secondary Outcomes

Prothrombin Time (PT)

Prothrombin Time blood levels

Time frame: 30 days

Activated Partial Thromboplastin Time (APTT)

Activated Partial Thromboplastin Time blood levels

Time frame: 30 days

Thrombin Time (TT)

Thrombin Time blood levels

Time frame: 30 days

Fibrinogen

Functional fibrinogen blood levels

Time frame: 30 days

Lactate

Lactate blood levels

Time frame: 30 days

Base Excess (BE)

Base Excess blood levels

Time frame: 30 days

Fibrin monomers

Fibrin monomers blood levels

Time frame: 30 days

Factor XII

Factor XII blood levels

Time frame: 30 days

Factor VIII

Factor VIII blood levels

Time frame: 30 days

Central Contacts

Patricia Guilabert, MD

CONTACT

0034934 89 30 00 patricia.guilabert@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.